The genetics of kidney transplantation

Human Genetics

Volumn 131, Issue 3, 2012, Pages 317-323

  Pallet, Nicolas ^a,b   Thervet, Eric ^a,b  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FAS ANTIGEN; FC RECEPTOR IIA; GAMMA INTERFERON; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MERCAPTOPURINE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 2; TACROLIMUS; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ALLOTYPE; ANTIGEN RECOGNITION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERANCE; EPIGENETICS; FOLLOW UP; GENE EXPRESSION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; GRAFT SURVIVAL; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; OUTCOME ASSESSMENT; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; RACE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; GENETIC VARIABILITY; GENETICS; GRAFT REJECTION; INTERDISCIPLINARY COMMUNICATION; METHODOLOGY;

GENETIC VARIATION; GENOTYPE; GRAFT SURVIVAL; HOST VS GRAFT REACTION; INTERDISCIPLINARY COMMUNICATION; KIDNEY TRANSPLANTATION; RESEARCH DESIGN;

EID: 84859508255     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-011-1092-8     Document Type: Review

References (48)

1. Anglicheau D, Pallet N, Rabant M, Marquet P, Cassinat B, Meria P, Beaune P, Legendre C, Thervet E (2006) Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction. Kidney Int 70:1019-1025
2. Anglicheau D, Legendre C, Beaune P, Thervet E (2007) Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8:835-849
3. Bamoulid J, Courivaud C, Deschamps M, Mercier P, Ferrand C, Penfornis A, Tiberghien P, Chalopin JM, Saas P, DuclouxD(2006) IL-6 promoter polymorphism-174 is associated with new-onset diabetes after transplantation. J Am Soc Nephrol 17:2333-2340
4. BrownKM,Kondeatis E,VaughanRW,Kon SP, Farmer CK, Taylor JD, He X, Johnston A, Horsfield C, Janssen BJ, Gros P, ZhouW, Sacks SH, SheerinNS (2006) Influence of donor C3 allotype on late renaltransplantation outcome. N Engl J Med 354:2014-2023
5. Cattaneo D, Ruggenenti P, Baldelli S, Motterlini N, Gotti E, Sandrini S, Salvadori M, Segoloni G, Rigotti P, Donati D, Perico N, Remuzzi G (2009) ABCB1 genotypes predict cyclosporinerelated adverse events and kidney allograft outcome. J Am Soc Nephrol 20:1404-1415
6. Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P, Nayir A, Bakkaloglu A, Ozen S, Sanjad S, Nelson-Williams C, Farhi A, Mane S, Lifton RP (2009) Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 106:19096-19101
7. Cipollone F, Toniato E, Martinotti S, Fazia M, Iezzi A, Cuccurullo C, PiniB,Ursi S, Vitullo G, Averna M, ArcaM, Montali A,Campagna F, Ucchino S, Spigonardo F, Taddei S, Virdis A, Ciabattoni G, Notarbartolo A, Cuccurullo F, Mezzetti A (2004) A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291:2221-2228
8. Cirulli ET, Singh A, Shianna KV, Ge D, Smith JP, Maia JM, Heinzen EL, Goedert JJ, Goldstein DB (2010) Screening the human exome: a comparison of whole genome and whole transcriptome sequencing. Genome Biol 11:R57
9. Copeland KR, Thliveris JA, Yatscoff RW (1990) Toxicity of cyclosporine metabolites. Ther Drug Monit 12:525-532
10. Coto E, Tavira B (2009) Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 88:S62-S67
11. Courivaud C, Bamoulid J, Loupy A, Deschamps M, Ferrand C, Le Corre D, Tiberghien P, Chalopin JM, Legendre C, Thervet E, Saas P, Ducloux D (2009a) Influence of cyclooxygenase-2 (COX-2) gene promoter polymorphism-765 on graft loss after renal transplantation. Am J Transplant 9:2752-2757
12. Courivaud C, Bamoulid J, Tiberghien P, Saas P, Chalopin JM, Ducloux D, Legendre C, Thervet E (2009b) G-765C COX-2 gene promoter polymorphism and risk of atherosclerosis after kidney transplantation. Transplantation 88:851-852
13. Ducloux D, Deschamps M, Yannaraki M, Ferrand C, Bamoulid J, Saas P, Kazory A, Chalopin JM, Tiberghien P (2005) Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 67:2454-2461
14. el-Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA (2004) A prospective, randomized study of coadministration of ketoconazole and cyclosporine a in kidney transplant recipients: ten-year follow-up. Transplantation 77:1371-1376
15. El-Dahshan KF, Bakr MA, Donia AF, Badr Ael S, Sobh MA (2006) Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. Am J Nephrol 26:293-298
16. Frazer KA, Murray SS, Schork NJ, Topol EJ (2009) Human genetic variation and its contribution to complex traits. Nat Rev Genet 10:241-251
17. Ghisdal L, Baron C, Le Meur Y, Lionet A, Halimi JM, Rerolle JP, Glowacki F, Lebranchu Y, Drouet M, Noel C, El Housni H, Cochaux P, Wissing KM, Abramowicz D, Abramowicz M (2009) TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol 20:2459-2467
18. Goldfarb-Rumyantzev AS, NaimanN(2008) Genetic prediction of renal transplant outcome. Curr Opin Nephrol Hypertens 17:573-579
19. Goldfarb-Rumyantzev AS, Naiman N (2010) Genetic predictors of acute renal transplant rejection. Nephrol Dial Transplant 25:1039-1047
20. Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, Rashford M, Nasmyth-Miller C, Voulgari A, Spleiss O, Truman M, Essioux L (2008) Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 21:879-891
21. Hauser I, Schaeffeler E, Gauer S, Scheuermann E, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zaner U, Geiger H, Eichelbaum M, Schwab M (2005) ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 16:1501-1511
22. Kang ES, Kim MS, Kim YS, Kim CH, Han SJ, Chun SW, Hur KY, Nam CM, Ahn CW, Cha BS, Kim SI, Lee HC (2008) A polymorphism in the zinc transporter gene SLC30A8 confers resistance against posttransplantation diabetes mellitus in renal allograft recipients. Diabetes 57:1043-1047
23. Kurzawski M, Dziewanowski K, Kedzierska K, Gornik W, Banas A, Drozdzik M (2010) Association of calpain-10 gene polymorphism and posttransplant diabetes mellitus in kidney transplant patients medicated with tacrolimus. Pharmacogenomics J 10:120-125
24. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y (2007) CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 82:711-725
25. La Manna G, Cappuccilli ML, Cianciolo G, Conte D, Comai G, Carretta E, Scolari MP, Stefoni S (2010) Cardiovascular disease in kidney transplant recipients: the prognostic value of inflammatory cytokine genotypes. Transplantation 89:1001-1008
26. Lee JP, Bae JB, Yang SH, Cha RH, Seong EY, Park YJ, Ha J, Park MH, Paik JH, Kim YS (2011) Genetic predisposition of donors affects the allograft outcome in kidney transplantation; polymorphisms of stromal-derived factor-1 and CXC receptor 4. PLoS One 6:e16710
27. Leite JL, Manfrinatto JA, Mazzali M, Ward LS (2006) Polymorphisms at exon 4 of p53 and the susceptibility to herpesvirus types 6 and 1 infection in renal transplant recipients. Transpl Int 19:732-737
28. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, McCarthy MI, Ramos EM, Cardon LR, Chakravarti A, Cho JH, Guttmacher AE, Kong A, Kruglyak L, Mardis E, Rotimi CN, Slatkin M, Valle D, Whittemore AS, Boehnke M, Clark AG, Eichler EE, Gibson G, Haines JL, Mackay TF, McCarroll SA, Visscher PM (2009) Finding the missing heritability of complex diseases. Nature 461:747-753
29. McLeod HL, Siva C (2002) The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 3:89-98
30. Metalidis C, Lerut E, Naesens M, Kuypers DR (2010) Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. Transplantation 91:1098-1102
31. Metzker ML (2010) Sequencing technologies-the next generation. Nat Rev Genet 11:31-46
32. Michelon H, Konig J, Durrbach A, Quteineh L, Verstuyft C, Furlan V, Ferlicot S, Letierce A, Charpentier B, Fromm MF, Becquemont L (2010) SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics 11:1703-1713
33. Moore J, McKnight AJ, Simmonds MJ, Courtney AE, Hanvesakul R, Brand OJ, Briggs D, Ball S, Cockwell P, Patterson CC, Maxwell AP, Gough SC, Borrows R (2010) Association of caveolin-1 gene polymorphism with kidney transplant fibrosis and allograft failure. JAMA 303:1282-1287
34. Ozsolak F, Milos PM (2011) RNA sequencing: advances, challenges and opportunities. Nat Rev Genet 12:87-98
35. Perkins D, Verma M, Park KJ (2011) Advances of genomic science and systems biology in renal transplantation: a review. Semin Immunopathol 33:211-218
36. Reeves-Daniel AM, DePalma JA, Bleyer AJ, Rocco MV, Murea M, Adams PL, Langefeld CD, Bowden DW, Hicks PJ, Stratta RJ, Lin JJ, Kiger DF, Gautreaux MD, Divers J, Freedman BI (2010) The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 11:1025-1030
37. Roby KA, Shaw LM (1993) Effects of cyclosporine and its metabolites in the isolated perfused rat kidney. J Am Soc Nephrol 4:168-177
38. Soulillou JP, Giral M (2006) Influence of graft characteristics on the outcome of kidney transplantation. N Engl J Med 354:2060-2062
39. Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, Toupance O, Touchard G, Alberti C, Le Pogamp P, Moulin B, Le Meur Y, Heng AE, Subra JF, Beaune P, Legendre C (2010) Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther 87:721-726
40. Turka LA, Wood K, Bluestone JA (2010) Bringing transplantation tolerance into the clinic: lessons from the ITN and RISET for the Establishment of Tolerance consortia. Curr Opin Organ Transplant 15:441-448
41. Vanrenterghem YF, Claes K, Montagnino G, Fieuws S, Maes B, Villa M, Ponticelli C (2008) Risk factors for cardiovascular events after successful renal transplantation. Transplantation 85:209-216
42. Varagunam M, Yaqoob MM, Dohler B, Opelz G (2009) C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med 360:874-880
43. Wahrmann M, Dohler B, Ruhenstroth A, Haslacher H, Perkmann T, Exner M, Rees AJ, Bohmig GA (2011) Genotypic diversity of complement component C4 does not predict kidney transplant outcome. J Am Soc Nephrol 22:367-376
44. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, Fu J, Shah T, Pravica V, Hutchinson IV, Burckart GJ (2008) IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 83:711-717
45. Weber LT, Hoecker B, Armstrong VW, Oellerich M, Tonshoff B (2008) Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. Ther Drug Monit 30:570-575
46. Werner T (2010) Next generation sequencing in functional genomics. Brief Bioinform 11:499-511
47. Woillard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Marquet P (2010) Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther 88:95-100
48. Yang J, Hutchinson II, Shah T, Min DI (2011) Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 91:1114-1119